Hospice Palliative Care Program
Symptom Guidelines

Dehydration
Dehydration

☐ Rationale

This guideline is adapted for inter-professional primary care providers working in various settings in Fraser Health, British Columbia and the Fraser Valley Cancer Center and any other clinical practice setting in which a user may see the guidelines as applicable.

Dehydration in the last days may bring about relief from previously distressing symptoms. It has been proposed that the fluid and electrolyte imbalances of dehydration may serve as a natural anesthetic to reduce the patient’s suffering.\(^1\)\(^-\)\(^13\)

☐ Scope

This guideline provides recommendations for the assessment and symptom management of adult patients (age 19 years and older) living with advanced life threatening illness and experiencing the symptom of dehydration in the last days. This guideline does not address disease specific approaches in the management of dehydration.

☐ Definition of Terms

- “Withdrawing from food and fluid is a common, natural part of the dying process”.\(^1\)
- Dehydration is a common condition that is associated with the following conditions; thirst, dry mouth, fatigue, constipation and decreased cognition which may not be attributable to dehydration alone. Low fluid intake has not shown to predict the severity of these symptoms.\(^1\)\(^,\)\(^3\)\(^,\)\(^5\)\(^,\)\(^7\)\(^,\)\(^10\)\(^,\)\(^14\)-\(^17\)
- Medically, dehydration is a serious and potentially life-threatening condition in which the body contains an insufficient volume of water for normal functioning. The term “volume depletion” is similar to dehydration, but it refers to the loss of salts as well as water.\(^18\)

☐ Standard of Care

1. Assessment
2. Diagnosis
3. Education
4. Treatment
**Recommendation 1  Assessment of Dehydration**

Ongoing comprehensive assessment is the foundation of effective dehydration management, including interview, physical assessment, medication review, medical and surgical review, psychosocial and physical environment review and appropriate diagnostics\(^{1-6, 9, 13-15, 17, 19, 20}\) (see Table 1).

*Table 1: Dehydration Assessment using Acronym O, P, Q, R, S, T, U and V*

<table>
<thead>
<tr>
<th><strong>Onset</strong></th>
<th>When did you start to feel dehydrated? Have you experienced it before?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Provoking / Palliating</strong></td>
<td>What brought it on? What makes it better? What makes it worse?</td>
</tr>
<tr>
<td><strong>Quality</strong></td>
<td>What does it feel like (dry mouth / skin, thirst)? Can you describe it?</td>
</tr>
<tr>
<td><strong>Region / Radiation</strong></td>
<td>Where is it affecting or bothering you?</td>
</tr>
<tr>
<td><strong>Severity</strong></td>
<td>What is the intensity of this symptom (On a scale of 0 to 10 with 0 being none and 10 being worst possible)? Right Now? At Best? At Worst? On Average? How bothered are you by this symptom? Are there any other symptom(s) that accompany this symptom?</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>What medications and treatments are you currently using? How effective are these? Do you have any side effects from the medications and treatments? What medications and treatments have you used in the past?</td>
</tr>
<tr>
<td><strong>Understanding / Impact on You</strong></td>
<td>What do you believe is causing this symptom? How is this symptom affecting you and / or your family?</td>
</tr>
<tr>
<td><strong>Values</strong></td>
<td>What is your goal for this symptom? What is your comfort goal or acceptable level for this symptom (On a scale of 0 to 10 with 0 being none and 10 being worst possible)? Are there any other views or feelings about this symptom that are important to you or your family?</td>
</tr>
</tbody>
</table>

* Physical Assessment (as appropriate for symptom)
Dehydration

Recommendation 2 Diagnosis

Intervention aimed at reducing dehydration must take into account the cause (often multi-factorial) of the symptom, the disease trajectory and the patient / family values and goals of care.\(^{(1, 3, 7, 13-16, 19-21)}\)

Reversible:

- **Nausea and / or vomiting** – reduced intake
- **Diarrhea** – malabsorption
- **Gastrointestinal Obstruction** – reduced intake and malabsorption
- **Anorexia** – reduced intake
- **Infection** – increases insensible losses, reduced intake
- **Hypercalcemia Medications** – diuretics increase urinary losses

Non-Reversible:

- **Terminal / end-stage disease or illness**

Recommendation 3 Education

Provide anticipatory guidance and / or education whenever possible to alleviate distress about hydration status: \(^{(1, 4, 8, 16)}\)

- Oral intake will lessen over time related to changes in metabolism and body requirements.\(^{(3-5, 19)}\)
- Parenteral fluid does not equal nutrition.\(^{(22)}\)
- Hydration has little or no effect on sensation of thirst and dry mouth.\(^{(1, 3, 6, 9, 15, 20)}\)
- Teach interventions that provide relief from thirst and / or dry mouth such as oral care, offering fluids, ice chips, chewing gum, mist or spraying mouth, lubrication of lips and skin care so family can contribute to care (if desired).\(^{(1, 5, 6, 8, 10, 12)}\)
- Some situations may dictate the need for a team and family conference.\(^{(19)}\)
- Resources for patients considering the benefits and burdens of parenteral hydration.\(^{(23, 24)}\)
Recommendation 4  Treatment

Goal of treatment should be to conserve or restore the best quality of life. It should be made on an individual basis taking into consideration the potential risks and benefits and should be reviewed daily. (1-4, 7-11, 14, 15, 17, 19, 20, 25)

Management of Dehydration

- Good oral care should be provided by family or caregivers. (1, 8, 9, 11, 12, 15, 26)
- Offer oral fluids (with or without lemon), ice chips or mist / spray to hydrate oral tissues. (1, 2, 9, 26)
- When oral intake is severely restricted, parenteral hydration (example – hypodermoclysis) may be indicated:
  - For patients in good symptom control when maintenance of cognitive status is important. (26)
  - To avoid medication side effects such as myoclonus, discontinuing hydration once side effect resolves or the terminal phase is reached. (3)
- A short trial of rehydration with clear goals and time frame (48 to 72 hours) to assess relief of symptoms that may be caused by dehydration. (1, 2, 6, 10, 14, 15, 22, 25, 26)

Hydration

Clinical studies suggest that terminally ill cancer patients may achieve adequate hydration with much lower volumes (as low as one litre per day) than recommended for the average medical and surgical patient due to: (14, 20)

- Decreased body weight.
- Decreased free water clearance.
- Decreased insensible water losses due to decreased physical activity.

Appropriate Use of Parenteral Fluids

Theoretical advantages (1, 7, 10-13, 19-21, 27)

- May relieve thirst and improve oral comfort.
- Improved renal function will lead to increased clearance of drugs and toxic metabolites.
- May facilitate resolution of reversible conditions (hypercalcemia, opioid neurotoxicity).
- Facilitates productive cough and thereby improves clearing of secretions.
- Improves function of unobstructed bowel.
- May improve delirium and / or terminal agitation, leading to better communication with family.
- Satisfies family’s need to provide nourishment and “do everything that can be done”.

Dehydration

Hospice Palliative Care Program • Symptom Guidelines
Theoretical disadvantages\(^{(1, 7, 10-13, 19, 20, 27)}\)

- Oral secretions causing need for suctioning.
- Urine output causing bed-wetting and bedpans or catheters.
- Respiratory tract secretions causing cough, respiratory congestion.
- Gastrointestinal secretions causing vomiting.
- Edema may contribute to pressure sores.
- May prolong the agonal period without prolonging life.
- Places physical barriers between the patient and family which can inhibit physical contact with the patient.
- Medicalization of dying forcing the patient to be admitted to facility.

Hypodermoclysis (HDC) – the subcutaneous administration of fluid, can be considered for rehydration.

- Hypodermoclysis is a safe and effective way of providing parenteral hydration.\(^{(27)}\)
- Criteria for selecting patients:
  - Unable to ingest sufficient amounts of fluid orally, is dehydrated and has distressing symptoms that diminish quality of life.\(^{(26, 28-31)}\)
  - Intravenous access is not required, possible or practical.\(^{(30, 31)}\)
  - Patient and / or family wish patient to receive hydration by this route.\(^{(28, 29)}\)
  - Patient does not require either immediate or high volume fluid replacement.\(^{(12, 29, 32, 33)}\)
  - Patient does not have respiratory congestion, large ascites or extensive edema.\(^{(29)}\)
  - Patient does not have coagulation problem or bleeding.\(^{(29, 30, 32, 34)}\)
- Standards of Practice:
  - The patient will be assessed to determine whether hydration is indicated. Dehydration alone is not a sufficient reason to offer hypodermoclysis. Confusion, delirium and myoclonus are often caused by the accumulation of toxic metabolites of drugs (such as opioids) and may be improved or relieved by rehydration.\(^{(26, 32, 33)}\)
  - Prior to initiation of hypodermoclysis, a discussion should take place with the patient and family / caregiver to explain the benefits and burdens of hydration, clarify expectations and delineate clear goals. If hypodermoclysis is being offered on a trial basis or for a limited time period the parameters must be explained to the patient and family and indications for discontinuing hypodermoclysis will be discussed prior to its initiation.\(^{(13, 28, 35, 36)}\)
  - Hypodermoclysis can be administered as an overnight infusion\(^{(29, 36)}\), as a bolus\(^{(19, 29, 30, 36, 37)}\) or by continuous infusion.\(^{(19, 29-32, 37)}\)
Dehydration

**Recommended volume maximum 1 to 1.5 litres**\(^{(26, 29)}\) of an isotonic solution daily;
- Normal Saline (0.9\%)\(^{(19, 26, 37)}\)
- 2/3 Dextrose (5\%) – 1/3 Normal Saline (0.9\%)\(^{(19, 26)}\)
- D5½NS\(^{(29, 31)}\)
- Ringers Lactate\(^{(31)}\)
- D5W should **not** be used as it becomes hypotonic as the dextrose is absorbed\(^{(32, 37)}\)
- Potassium chloride up to 40 mEq per litre may be added to the solution\(^{(26, 29, 30)}\)
- Hyaluronidase is no longer felt to be justified\(^{(30)}\) or necessary\(^{(19, 26, 36, 37)}\) for routine bolus hydration and is no longer available in Canada.

**Recommended sites for hypodermoclysis** (ask patient which site is preferred);
- Upper chest, back (below scapula), thigh and upper abdominal wall\(^{(12, 30-32)}\)
- Do not insert needle for hypodermoclysis into previously irradiated skin as absorption may be impaired.
- For ambulatory patients consider using chest, scapular region and abdomen and for patients limited to bed-rest use thighs and abdomen\(^{(12)}\)
- Avoid anterior or lateral thigh if edema present; abdomen if ascites present; breast tissue; lateral placement near shoulder; arms (32, 34) and perineum / groin\(^{(36)}\)

**I.V. route** should be limited to situations where the subcutaneous administration of fluids is contraindicated: generalized edema or coagulation disorders and patients requiring I.V. for other purposes\(^{(1, 7, 14)}\)

Rehydration in patients with CHF, extensive edema and hypoalbuminaemia should be undertaken with care\(^{(1, 7, 15, 16, 20)}\)
Dehydration

References

Information was compiled using the CINAHL, Medline (1996 to April 2006) and Cochrane DSR, ACP Journal Club, DARE and CCTR databases, limiting to reviews / systematic reviews, clinical trials, case studies and guidelines / protocols using dehydration terms in conjunction with palliative / hospice / end of life / dying. Palliative care textbooks mentioned in generated articles were hand searched. Articles not written in English were excluded.

Dehydration

Hospice Palliative Care Program • Symptom Guidelines


Approved by: Hospice Palliative Care, Clinical Practice Committee, November 24, 2006